Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sihuan Pharma In-Licenses Two CCV Products from NeuroVive of Sweden

publication date: Nov 20, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sihuan Pharmaceutical, China’s largest cerebral-cardiovascular drugmaker, bought China rights to two clinical-stage drugs from NeuroVive Pharmaceutical AB of Sweden: CicloMulsion® treats heart reperfusion injuries and NeuroSTAT® is given to patients who have suffered a traumatic brain injury. Sihuan will pay 47 million RMB ($7.2 million) for the two products in a combination of upfront and milestone payments. It will also pay a royalty of 10% on revenues for ten years from launch. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners